← Leaderboards
Michael J Overman
University Of Tx Md Anderson Can Ctr
$2,432,364
Attributed
$4,607,912
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,607,912 · 4
By mechanism
R01$2,976,222 · 1
P50$1,248,890 · 2
R21$382,800 · 1
Top collaborators
- Susan K Peterson5 shared
- Kanwal Raghav5 shared
- Donghui Li2 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Scott Kopetz$13,199,822
- Eduardo Vilar Sanchez$16,310,319
- Laszlo George Radvanyi$2,629,361
- Willem W Overwijk$2,740,328
- Gregory A Lizee$3,884,952
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectClinical TrialsCancer PatientMonitorDigitalCessation Of LifeFutureColorectal CancerMutateTumorResponseMutationMetastatic ColorectalPre-ClinicalClinical Decision-MakingFitnessEvidence BaseFundingGuidelinesDisease ProgressionAssessment ToolEastern Cooperative Oncology GroupAdvanced Malignant NeoplasmDevices
Grant awards (11)
A technological approach for performance status assessment in advanced cancer patients$546,557
R01 · FY2024 · CA
A technological approach for performance status assessment in advanced cancer patients$559,111
R01 · FY2023 · CA
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.$332,973
P50 · FY2023 · CA · contact PI
A technological approach for performance status assessment in advanced cancer patients$554,559
R01 · FY2022 · CA
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.$329,047
P50 · FY2022 · CA · contact PI
A technological approach for performance status assessment in advanced cancer patients$643,610
R01 · FY2021 · CA
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.$248,431
P50 · FY2021 · CA · contact PI
A technological approach for performance status assessment in advanced cancer patients$672,385
R01 · FY2020 · CA
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.$338,439
P50 · FY2020 · CA · contact PI
KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer$174,000
R21 · FY2017 · CA
KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer$208,800
R21 · FY2016 · CA